Show simple item record

Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide

dc.contributor.authorOrkin, Cen_US
dc.contributor.authorAntinori, Aen_US
dc.contributor.authorRockstroh, Jen_US
dc.contributor.authorGuillen, SMen_US
dc.contributor.authorMartorell, Cen_US
dc.contributor.authorMolina, J-Men_US
dc.contributor.authorLazzarin, Aen_US
dc.contributor.authorMaggiolo, Fen_US
dc.contributor.authorYazdanpanah, Yen_US
dc.contributor.authorAndreatta, Ken_US
dc.contributor.authorHuang, Hen_US
dc.contributor.authorHindman, Jen_US
dc.contributor.authorMartin, Hen_US
dc.contributor.authorBaeten, Jen_US
dc.contributor.authorPozniak, Aen_US
dc.date.accessioned2023-11-16T13:46:39Z
dc.date.available2023-11-16T13:46:39Z
dc.date.issued2023en_US
dc.identifier.issn1464-2662en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/91966
dc.format.extent21 - 22en_US
dc.titleOutcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamideen_US
dc.typeConference Proceeding
pubs.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:001042880500029&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume24en_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record